Biohaven Ltd. today announced enrollment of the first patient in the pivotal Phase 3 trial of BHV-1300 for Graves' disease. BHV-1300 is the first MoDE extracellular protein degrader, a novel small ...

When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no ...

Anthropic’s new Claude research reveals a hidden internal “global workspace” that resembles human conscious processing, ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...

An analytical guide to cellular optimization, epigenetic switches, and the daily disciplines that preserve youth from the ...

Millions of people taking semaglutide and similar GLP-1 receptor agonists for diabetes or weight loss may also be ...

Abstract: A 50-Mb/s quadrature phase-shift keying (QPSK)/offset quadrature phase-shift keying (O-QPSK) transmitter suitable for biomedical high-quality imaging application is presented. Centered at ...

Abstract: We present an analog subsampling PLL based on a digital-to-time converter (DTC), which operates with almost no performance gap (176/198 fs RMS jitter) between the integer and the worst case ...

Adaptive as well as innate immune responses contribute to the development of atherosclerosis. Studies performed in experimental animals have revealed that some of these immune responses are protective ...

Introduction As the number of female athletes competing rises globally, training methodologies should reflect sex differences across critical metrics of adaptation to training. Surrogate markers of ...

Eisai Co., Ltd. announced today the company will present the latest findings from its Alzheimer’s disease (AD) research, including lecanem ...